PPHM. Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2013 Financial Results and Recent Developments Interim Data Show Doubling of Median Overall Survival in Bavituximab-Treated Patients from Double-Blind, Placebo-Controlled Phase II Trial in Second-Line Non-Small Cell Lung Cancer; Recent Data Strongly Support Advancing Bavituximab Program Into Phase III Clinical Development http://finance.yahoo.com/news/peregrine-pharmaceuticals-reports-first-quarter-130611753.html
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.